Greg Budoff, MD
Retina Specialist · Manchester, CTNPI 1700239530
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,154 of the $4,622 with a category attached, or 89.9%. It is spread thinly across 15 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,675, 2.1 times the $795 reported in 2021.
Across 113 payments — averaging $40.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$896
- Genentech USA, Inc.$733
- AbbVie$715
- Alcon$566
- Dutch Ophthalmic, USA$356
- Apellis Pharmaceuticals, Inc.$283
- plus $1K from 9 others
What the payments were for
- Food & beverage$4,15490%
- Other$46810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 20 | $896 |
| Genentech USA, Inc. | 26 | $733 |
| AbbVie(2 entities) | 25 | $715 |
| Alcon | 2 | $566 |
| Dutch Ophthalmic, USA | 3 | $356 |
| Apellis Pharmaceuticals, Inc. | 7 | $283 |
| Alimera Sciences, Inc. | 9 | $250 |
| Regeneron | 3 | $183 |
| ANI Pharmaceuticals, Inc. | 9 | $174 |
| Genentech, Inc. | 1 | $145 |
| Novartis | 1 | $125 |
| Bausch & Lomb Americas Inc. | 4 | $70 |
| Ocular Therapeutix, Inc. | 1 | $50 |
| Astellas Pharma US Inc | 1 | $45 |
| Harrow Eye, LLC | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few retina specialist providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 126 | $8,902 |
| Atropine Sulfate | 81 | $3,170 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 93 | $672 |
| Latanoprost | 28 | $495 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $182 |
| Cyclopentolate Hcl | 12 | $98 |
| Brimonidine Tartrate | 14 | $54 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Manchester
- Scott WalterManchester$312K
- Nauman ChaudhryWaterford$4K
- Armand DaccacheDanbury$3K
- Stephanie SuginWaterbury$2K
- Richard ScartozziDanbury$2K
- Craig SklarWaterbury$2K
- Tomasz WiraszkaWaterbury$2K
- Vincent ReppucciDanbury$1K
- Juner Colina BiscottoWaterford$1K
- Jennifer NadelmannNew Haven$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.